GlassScriptPhysician profile
Keith L Kidd
NPI 1811168941
$5,221.70
in general payments reported to CMS, 2019-2025
31 companies · $1,542 in 2025
The $1,542 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,001 · 2022: $936 · 2023: $710 · 2024: $1,033 · 2025: $1,542.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,284 · Education: $1.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,283.52 |
| Education | $1.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,280.77 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $1,150.84 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $480.44 | 2022-2025 | |
| Axsome Therapeutics, INC. | $384.95 | 2024-2025 | Auvelity, Sunosi |
| Lilly USA, LLC | $275.08 | 2021-2024 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $267.21 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $240.48 | 2021-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $174.08 | 2024 | Fanapt |
| Pfizer INC. | $147.52 | 2021-2022 | |
| Amgen INC. | $103.90 | 2022-2025 | Otezla, Repatha, Repatha |
| Almatica Pharma LLC | $90.43 | 2024-2025 | Loreev Xr |
| Novo Nordisk INC | $67.00 | 2021-2024 | Wegovy |
| Scilex Pharmaceuticals INC. | $56.58 | 2021-2023 | Ztlido |
| Lundbeck LLC | $51.50 | 2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $50.85 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $45.82 | 2021-2022 | |
| Glaxosmithkline, LLC. | $39.81 | 2021-2023 | Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $39.53 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $31.11 | 2023-2025 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.08 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $30.52 | 2022 | |
| Amarin Pharma, INC. | $29.44 | 2021 | |
| Boston Scientific Corporation | $21.19 | 2021 | |
| Alkermes, INC. | $20.96 | 2023 | Lybalvi |
| Shield Therapeutics INC | $20.52 | 2024 | |
| Medtronic, INC. | $19.84 | 2024 | Venaseal |
| E.R. Squibb & Sons, L.L.C. | $19.29 | 2023 | |
| Exact Sciences Corporation | $18.15 | 2023 | Cologuard Collection Kit |
| Paratek Pharmaceuticals, INC. | $15.78 | 2023 | Nuzyra |
| Abbott Laboratories | $15.37 | 2025 | Freestyle Libre 3 |
| Travere Therapeutics, INC. | $1.66 | 2025 | Filspari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Kidd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.